You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction
SBC: APC BIO INNOVATIONS INC Topic: NHLBIAbstract Over 5,000 lung transplants (LTx) are performed in the US each year to save the lives of patients in respiratory failure due to COPD, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and other terminal lung conditions. The vast majority of LTx, long-term survival is significantly limited by chronic lung allograft dysfunction (CLAD) with a median survival of 6 years ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Regulatory clearance of the Glide Control Strategy for Upper Limb Prostheses
SBC: INFINITE BIOMEDICAL TECHNOLOGIES, LLC Topic: NICHDRegulatory clearance of the Glide Control Strategy for Upper Limb Prostheses ABSTRACT There is a pressing need to improve control of myoelectric prostheses for individuals with upper limb loss (ULL). To date, only two fundamental control methods have been made commercially available – Direct Control (DC, introduced in 1960) and Pattern Recognition (PR, introduced in 2016). Both have significant ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines
SBC: SANARIA INC. Topic: NIAIDProject Abstract In 2020 malaria cases (241M) and deaths (627,000) reached the highest since 2012 emphasizing the urgent need for new tools for prevention, control, and elimination of this disease. Sanaria’s Plasmodium falciparum (Pf) sporozoite (SPZ) Vaccine, composed of radiation attenuated PfSPZ administered by intravenous injection, assessed in 1740 subjects aged 5 months to 61 years in 6 co ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
SBC: Rise Therapeutics, LLC Topic: NIAIDProject Summary Our goal is to develop a novel, immunological-directed synthetic biology-based therapeutic for the treatment of Multiple Sclerosis (MS). MS is a devastating characterized by an exacerbated immune response that destroy myelin. This disease affects many important aspects of a patient's life, including emotional well-being, quality of life, working ability, and social interactions. In ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Pharmaceutical development of longer-lasting brimonidine eye drops
SBC: Novus Vision LLC Topic: NEIPROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive Diagnostic Markers of Lower Respiratory Tract Infection in Mechanically Ventilated Patients
SBC: Zeteo Tech, Inc. Topic: NIAIDProject Summary/Abstract Lower respiratory tract infection (LRTI) is the most common infectious cause of death. LRTI affects patients more often in ICUs, especially patients with mechanical ventilators. Early initiation of short-course antibiotic therapy is the cornerstone in managing mechanically ventilated patients with LRTI. However, using the current clinical criteria, a diagnosis of LRTI is t ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Metalloenzyme binding affinity prediction with VM2
SBC: VERACHEM LLC Topic: 400Project summary: It is estimated that 40 to 50% of known enzymes can be characterized as metalloenzymes, while currently only 7% of FDA-approved drugs in the United States target this class of protein. This is despite the fact that there are many dozens of already identified metalloenzyme targets involved in virtually every therapeutic area, including anti-inflammatory, antibiotics, antivirals, an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
SBC: PREVEP, LLC Topic: NINDSAbstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control
SBC: ABVACC, INC. Topic: NIAIDThe ebolaviruses (EBOV, SUDV, BDBV) and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with very high mortality rates. The 2013-2016 Ebola virus disease (EVD) outbreak in West Africa highlighted the serious nature of a filovirus epidemic and its regional and global implications. This outbreak took an enormous toll on people at the front line of the epide ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Simple and Accessible Microfluidic Platform for Single Molecule Sequence Profiling of Tumor-derived DNA within Liquid Biopsies
SBC: HYPERMELT, LLC Topic: 394Project Summary/ Abstract Over 600,000 people in the US will die from cancer this year. It is estimated that 25% of these deaths could have been prevented by detection in earlier stages. Implementation of minimally-invasive routine screening, such as pap smears for cervical cancer, has proven to be an effective approach for reducing cancer mortality. However, several challenges prevent successful ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health